- Members of Biden’s Pandemic Response Team Optimistic About Vaccine Rollout
- What Will COVID-19 Look Like Years From Now?
- Time to Angioplasty Is Crucial for Better Heart Attack Outcomes
- I’ve Already Had COVID-19, Do I Need the Vaccine?
- ‘Mindfulness’ on Your Mind? It Has Limits, Review Finds
- Many Americans Don’t See Links Between Racism, Health Outcomes: Poll
- Sperm Samples May Help Predict Autism Risk in Offspring
- AHA News: Baby Born With Heart Defect Faces More Challenges After Stroke
- U.S. COVID Vaccine Rollout Nears 1 Million Doses Per Day
- Health Highlights: Jan. 14, 2021
H5N1 Bird Flu Vaccine Approved
A new vaccine has been approved by the U.S. Food and Drug Administration to prevent the so-called “bird flu” virus in adults at greater-than-average risk of exposure, the FDA said.
While most strains of bird flu don’t infect people, the H5N1 virus has caused “serious illness and death in people outside of the U.S., mostly among people who have been in close contact with infected and ill poultry,” the agency said in a news release announcing the approval.
The shot, called the Influenza A (H5N1) Virus Monovalent Vaccine, has been developed “in the event that the H5N1 avian influenza virus develops the capability to spread efficiently from human to human, resulting in the rapid spread of the disease across the globe,” the FDA added.
The vaccine, produced by a Canadian subsidiary of GlaxoSmithKline, is not intended for commercial distribution, the FDA said. It’s designed to be administered in two doses given three weeks apart.
In clinical testing involving some 3,400 adults, the most common side effects included injection-site pain and swelling, muscle aches, headache and fatigue.
More information
To learn more about bird flu, visit flu.gov.
Source: HealthDay
